Melanoma surgery serves as the definitive treatment for primary cutaneous melanoma, a malignant cancer originating in pigment-producing skin cells called melanocytes. The core biological goal is complete surgical removal of cancer cells before they spread through lymphatic or blood vessels. According to National Comprehensive Cancer Network (NCCN 2024) guidelines, surgical resection provides the highest cure rate for localized melanoma. The scope of surgery depends on tumor thickness, micro-staging features, and anatomical location.

The patient is positioned, and the surgical field is sterilized. For wide local excision, local, regional, or general anesthesia is administered. The surgeon measures precise surgical margins surrounding the original biopsy scar based on tumor thickness guidelines. An elliptical incision is made down through subcutaneous fat to the underlying muscle fascia. The tissue specimen is marked with surgical sutures or dyes to aid the pathologist in orientation. If sentinel lymph node biopsy is performed, preoperative radiotracer injection (lymphoscintigraphy) and intraoperative blue dye administration guide the surgeon to the first drainage node. A small secondary incision over the nodal basin allows identification and removal of the radioactive or dyed sentinel node. The primary wound is closed directly in layers or repaired using a skin graft or local tissue flap. Drains may be placed for extensive dissections. Specimens are dispatched for histopathological evaluation.

Evidence-based clinical advantages of melanoma surgery include:

• High cure rate for localized disease: Early-stage melanoma treated with wide surgical excision demonstrates 5-year overall survival rates exceeding 95% (AJCC 8th Edition, 2017).
• Accurate pathological staging: Excision combined with sentinel lymph node biopsy provides critical information regarding micro-metastasis, directing further therapy options.
• Prevention of local recurrence: Standardized surgical margins significantly minimize the risk of local tumor persistence.
• Minimally invasive diagnostic assessment: Modern sentinel node mapping identifies nodal spread without necessitating immediate complete radical lymph node dissection.

Recovery from melanoma surgery varies based on excision size, anatomical location, and whether lymphatic staging or reconstructive skin grafting was performed. For standard wide local excision without grafting, primary wound healing occurs within 10 to 14 days, allowing suture removal. Patients typically resume non-strenuous daily activities within 48 to 72 hours. When skin grafts or local tissue flap rotations are required, immobilization of the surgical site may be necessary for 7 to 10 days, with full tissue maturation occurring over 6 to 12 months. Long-term recovery involves active scar monitoring and scheduled dermatologic surveillance.

Surgical resection addresses various forms and stages of cutaneous melanoma, including:

• Melanoma in situ: Pre-invasive melanoma confined entirely to the epidermal skin layer.
• Invasive cutaneous melanoma: Malignant melanoma extending into the dermis or subcutaneous fat layers.
• Subungual melanoma: Melanoma developing beneath nail beds of fingers or toes.
• Acral lentiginous melanoma: Melanoma occurring on non-hair-bearing skin surfaces such as palms and soles.
• Regional lymph node metastasis: Melanoma cells that have migrated to adjacent regional lymph nodal basins.
• Local recurrent melanoma: Cancer recurrence within or immediately adjacent to a previous surgical scar.

Preoperative preparation includes a full-body dermatologic examination and histological verification via biopsy. Blood tests, electrocardiograms, and imaging studies (such as ultrasound, CT, or PET-CT) may be ordered depending on staging. Patients must disclose all current medications, particularly anticoagulants (blood thinners) and antiplatelet agents, which may require temporary discontinuation under guidance. Smoking cessation is recommended at least 2 to 4 weeks prior to surgery to promote skin graft and wound healing. Fasting is required if general or regional anesthesia is scheduled.

Complications are stratified by severity. Common, mild side effects include localized pain, bruising, mild swelling, and temporary surgical site numbness. Moderate risks include wound infection, surgical site bleeding, wound dehiscence (separation of scar edges), and seroma or hematoma accumulation under skin flaps. Rare but serious risks involve permanent lymphedema (chronic swelling caused by impaired lymph fluid drainage) following lymph node removal, major wound necrosis requiring reconstructive re-operation, deep vein thrombosis, and risks related to general anesthesia.

The surgical journey for melanoma begins with a comprehensive diagnostic workup, including a biopsy, clinical skin examination, and risk stratification based on Breslow thickness—the measurement of tumor depth in millimeters. On the day of surgery, patients undergo wide local excision, often combined with lymphatic mapping and sentinel lymph node biopsy (SLNB) for tumors deeper than 0.8 mm. Surgery is typically performed in an outpatient setting under local, regional, or general anesthesia. Immediate postoperative care focuses on wound management and pain control. Surgical pathology results arrive within 7 to 14 days to determine if clear surgical margins were achieved and whether cancer cells exist in regional lymph nodes, guiding subsequent systemic therapies or surveillance plans.